Apogee Therapeutics is no longer just a potential takeover target because it has already entered into a definitive merger agreement to be acquired by AbbVie. Following competitive clinical data readouts and extensive valuation interest within the biotechnology sector, AbbVie initiated the multi-billion-dollar cash buyout transaction, which is scheduled to finalize pending customary regulatory approvals and shareholder sign-offs.